Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195779 | 0.87 | SIGMAR1 (0.57) | SIGMAR1CYP2D6ADRA1AHTR7 | |
| SCHEMBL5729369 | 0.82 | SIGMAR1 (0.58) | SIGMAR1CYP2D6ADRA1AHTR7 | |
| Propylamine SCHEMBL8638613 | 0.81 | ADRA1A (0.53) | SIGMAR1CYP2D6ADRA1AHTR7 | |
| SCHEMBL7245716 | 0.79 | CCR1 (0.54) | CCR1SIGMAR1CYP2D6ADRA1A | |
| SCHEMBL7243212 | 0.77 | OPRM1 (0.52) | SIGMAR1CYP2D6ADRA1AHTR7 | |
| SCHEMBL3628641 | 0.76 | ADRA1A (0.53) | CCR1SIGMAR1CYP2D6ADRA1AHTR7 | |
| SCHEMBL6196180 | 0.76 | HSD17B10 (0.57) | CCR1SIGMAR1ADRA1AHTR7ALDH1A1 | |
| SCHEMBL6955064 | 0.76 | SIGMAR1 (0.46) | SIGMAR1CYP2D6ADRA1AHTR7 | |
| SCHEMBL9394292 | 0.75 | HTR7 (0.48) | CCR1SIGMAR1ADRA1AHTR7ALDH1A1 | |
| SCHEMBL6686824 | 0.74 | SIGMAR1 (0.53) | SIGMAR1CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | CCR1 2951/4885SIGMAR1 534/4885CYP2D6 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.